1. Search Result
Search Result
Results for "

Hexokinase 2

" in MedChemExpress (MCE) Product Catalog:

4

Inhibitors & Agonists

1

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-134929

    Hexokinase Infection Cancer
    Hexokinase 2 inhibitor 1 (Compound 2a) is a hexokinase 2 (HK2) inhibitor with anti-tumor activity and can be used in cancer research .
    Hexokinase 2 inhibitor 1
  • HY-P10108

    Hxk2VBD peptide, cell-permeable

    Hexokinase Neurological Disease
    Hexokinase II VDAC binding domain peptide (Hxk2VBD peptide) is a cell-permeable hexokinase II VDAC binding domain. Hexokinase II VDAC binding domain peptide inhibits mitochondrial localization of hexokinase 2 (HXK2). Hexokinase II VDAC binding domain peptide inhibits neurotrophic factor-directed axon outgrowth .
    Hexokinase II VDAC binding domain peptide, cell-permeable
  • HY-W000133

    Amipaque

    Hexokinase Neurological Disease
    Metrizamide (Amipaque) is used as the contrast medium for angiography in neuroradiological investigations . Metrizamide inhibits human brain hexokinase .
    Metrizamide
  • HY-155008
    PROTAC HK2 Degrader-1
    2 Publications Verification

    Hexokinase Cancer
    PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine (HY-B0486) as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide (HY-14658) as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research .
    PROTAC HK2 Degrader-1